BCAB · BioAtla, Inc.
$3.09
-0.36 (-10.43%)
At close · Aug 14
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our current operating plan, and along with our history of operating losses, our current cash and cash equivalents are not sufficient to fund our ongoing operations for a period of at least twelve months from the date the condensed consolidated financial statements included in this report are issued, and these circumstances raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.15M
Shares
1.67M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-07-13 | 237 | $3.82 | $905 |
| 2026-07-06 | 57 | $4.19 | $239 |
| 2026-07-01 | 780 | $4.14 | $3,229 |
| 2026-06-30 | 1,602 | $3.83 | $6,136 |
| 2026-06-29 | 4,972 | $3.68 | $18,297 |
| 2026-06-26 | 6,023 | $3.55 | $21,382 |
| 2026-06-25 | 5,799 | $3.79 | $21,978 |
| 2026-06-23 | 3,335 | $3.62 | $12,073 |
| 2026-06-18 | 377 | $3.55 | $1,338 |
| 2026-06-17 | 421 | $3.45 | $1,452 |
| 2026-06-16 | 1,438 | $3.62 | $5,206 |
| 2026-06-15 | 4,559 | $3.86 | $17,598 |
| 2026-06-12 | 2,368 | $3.56 | $8,430 |
| 2026-06-11 | 1,568 | $3.65 | $5,723 |
| 2026-06-10 | 2,114 | $3.44 | $7,272 |
| 2026-06-09 | 897 | $3.31 | $2,969 |
| 2026-06-05 | 2,235 | $3.49 | $7,800 |
| 2026-06-04 | 1,737 | $3.40 | $5,906 |
| 2026-06-03 | 360 | $3.53 | $1,271 |
| 2026-06-01 | 1,876 | $3.93 | $7,373 |
| 2026-05-29 | 1,685 | $4.05 | $6,824 |
| 2026-05-28 | 1,700 | $3.73 | $6,341 |
| 2026-05-27 | 3,084 | $3.91 | $12,058 |
| 2026-05-20 | 1,607 | $3.87 | $6,219 |
| 2026-05-19 | 1,503 | $3.92 | $5,892 |
| 2026-05-18 | 286 | $4.27 | $1,221 |
Showing 1–26 of 26 settlements
Key facts
CIK
1826892
CUSIP
09077B203
13F (30d)
21 filings
21 filers
Visit website
Investor relations